FDA and Foreign Trial Monitoring: What the OIG Report Said-And What It Didn't
This article was originally published in RPM Report
Executive Summary
June's report from the Inspector General of the Department of Health and Human Services on foreign clinical trials is a stark reminder that the pharma industry's reputation problems are alive and unwell. Here is the storyline at its most basic: A global industry that conducts research in many countries to serve patients in many more does its product testing in many countries as well.